Tandem Diabetes (TNDM) Adds Peyton Howell to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus
July 30, 2020 4:21 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.45), $0.21 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $109.2 million versus the consensus estimate of $87.15 million.
We achieved our highest quarterly sales, successfully completed our first acquisition, and executed multiple meaningful agreements in support of our longer-term objectives in the second quarter, said John Sheridan,... More
